UOC
GNCA

UBS O'Connor’s Genocea Biosciences, Inc. GNCA Stock Holding History

UBS O'Connor’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,750,000
Closed -$1K – 455
2020
Q2 		$1K Buy
+1,750,000
New +$4.03M ﹤0.01% 390
2020
Q1 		– Sell
-1,750,000
Closed -$1K – 443
2019
Q4 		$1K Hold
1,750,000
– – ﹤0.01% 317
2019
Q3 		$5K Hold
1,750,000
– – ﹤0.01% 305
2019
Q2 		$20K Buy
+1,750,000
New +$9.13M ﹤0.01% 242

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS O'Connor's GNCA Position: Q3 2021 in Review

UBS O'Connor sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2021, closing a stake of 19,170 shares — an estimated $45K sold.

UBS O'Connor first reported a position in GNCA in Q3 2015 and held it in 10 quarters. The position peaked at $137K in Q3 2015. 40 funds tracked by Wall St. Rank hold GNCA as of Q3 2021.

  • UBS O'Connor reported no remaining Genocea Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • UBS O'Connor sold 19,170 Genocea Biosciences, Inc. shares in Q3 2021, an estimated $45K.
  • UBS O'Connor first reported a position in Genocea Biosciences, Inc. in Q3 2015 and held it in 10 quarters.
  • UBS O'Connor's Genocea Biosciences, Inc. position peaked at $137K in Q3 2015.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2021.

Based on UBS O'Connor's 13F filing for Q3 2021, filed 12 Nov 2021.